How many drugs treat anxiety?

Drug Landscape tracks 10 marketed treatments for anxiety (deduplicated by molecule). 0 Phase 3 candidates and 0 Phase 2 candidates are in the pipeline.

How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/anxiety.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

anxiety — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

anxiety (disease) competitive landscape: 10 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

10 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating anxiety, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Versed	midazolam	Generic (originally Roche)	Benzodiazepine (short-acting)	Multidrug resistance protein 1, Cytochrome P450 3A4, GABA A receptor alpha-3/beta-2/gamma-2	1985-12-20
Versed	Midazolam Hydrochloride	Takeda Pharmaceutical Company Limited	Benzodiazepine	GABA A receptor alpha-5/beta-2/gamma-2	1985-01-01
Prazene	PRAZEPAM	Parke Davis		GABA-A receptor alpha-1/beta-2/gamma-2	1982-01-01
Xanax	alprazolam	Generic (originally Upjohn/Pfizer)	Benzodiazepine (triazolobenzodiazepine)	Bromodomain-containing protein 4, Platelet-activating factor receptor, Cytochrome P450 3A4	1981-10-16
Paxipam	HALAZEPAM	Merck & Co.	halazepam	GABA-A receptor; anion channel	1981-01-01
Ativan	lorazepam	Generic (originally Wyeth/Pfizer)	Benzodiazepine [EPC]	GABA-A receptor alpha-1/beta-3/gamma-2, Fatty acid-binding protein, liver	1977-09-30
Tranxene	clorazepate	Ajenat Pharms	Benzodiazepine	GABA-A receptor alpha-1/beta-2/gamma-2	1972-01-01
Valium	diazepam	Generic (originally Roche)	Benzodiazepine [EPC]	Adenosine receptor A3, Aldo-keto reductase family 1 member C1, Aldo-keto reductase family 1 member C2	1963-11-15
Chlordiazepoxide Hydrochloride	CHLORDIAZEPOXIDE	Bausch Health	Benzodiazepine	Histamine H1 receptor	1960-01-01
Xanax	Xanax	National Taiwan University Hospital		Bromodomain-containing protein 4, Platelet-activating factor receptor, Cytochrome P450 3A4

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

· 8 drugs in anxiety
Generic (originally Roche) · 2 drugs in anxiety
Bausch Health · 1 drug in anxiety
Forces of Nature · 1 drug in anxiety
Generic (originally Upjohn/Pfizer) · 1 drug in anxiety
Generic (originally Wyeth/Pfizer) · 1 drug in anxiety
Merck & Co. · 1 drug in anxiety
National Taiwan University Hospital · 1 drug in anxiety
Parke Davis · 1 drug in anxiety
Takeda Pharmaceutical Company Limited · 1 drug in anxiety
Ajenat Pharms · 1 drug in anxiety

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in anxiety:

Cite this brief

Drug Landscape (2026). anxiety — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/anxiety. Accessed 2026-06-10.

anxiety full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing